RxDoctor Payments Data

Elena Lvov, APRN

Family · East Providence, RINPI 1023448925

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by GSK at 24.6% of the total. Reporting peaked in 2023 at $2,556 and has fallen 94.7% since, to $134 in 2025. Among family clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,000in general payments, 2019–2025

Across 295 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$755
  • Optinose US, Inc.$397
  • Pfizer$323
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$6,977100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,000 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$26,200
Medicare patients
196
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluticasone Propionate180$3,608
Ipratropium Bromide87$3,159
Azelastine Hcl61$2,166
Mometasone Furoate25$1,725
Montelukast Sodium46$609
Levocetirizine Dihydrochloride17$458

Paid to pharmacies, not to this prescriber.

Other family in East Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →